ProfileGDS5678 / 1445174_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 70% 71% 68% 70% 75% 75% 71% 70% 70% 71% 70% 72% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6837473
GSM967853U87-EV human glioblastoma xenograft - Control 24.4202870
GSM967854U87-EV human glioblastoma xenograft - Control 34.4721971
GSM967855U87-EV human glioblastoma xenograft - Control 44.1956768
GSM967856U87-EV human glioblastoma xenograft - Control 54.3809370
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.79875
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8955375
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.5084771
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3856570
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3377670
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4724671
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3840970
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.608372
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4720471